关于本次募集资金投向属于科技创新领域的说明 （修订稿） 北京华峰测控技术股份有限公司（以下简称"华峰测控"或"公司"）根据 《上市公司证券发行注册管理办法》等有关规定，结合公司本次向不特定对象 发行可转换公司债券方案及实际情况，对向不特定对象发行可转换公司债券募 集资金投向是否属于科技创新领域进行了研究，编制了《关于本次募集资金投 向属于科技创新领域的说明（修订稿）》（以下简称"本说明"）。 如无特别说明，本说明中相关简称与术语具有与《北京华峰测控技术股份 有限公司向不特定对象发行可转换公司债券预案（修订稿）》中相同的含义。 一、公司的主营业务 证券代码：688200 证券简称：华峰测控 北京华峰测控技术股份有限公司 公司主营业务为半导体自动化测试系统的研发、生产和销售。产品主要用 于模拟、数模混合、分立器件和功率模块等集成电路的测试，销售区域覆盖中 国大陆、中国台湾、美国、欧洲、日本、韩国、东南亚和印度等全球半导体产 业发达的国家和地区。 自成立以来，公司始终专注于半导体自动化测试系统领域，以自主研发的 产品实现了模拟及混合信号类半导体自动化测试系统的国产化，同时不断拓展 在氮化镓、碳化硅以及 IGBT 等 ...

证券代码：688200 证券简称：华峰测控 北京华峰测控技术股份有限公司 Beijing Huafeng Test & Control Technology Co.,Ltd. （北京市海淀区丰豪东路 9 号院 5 号楼 1 至 5 层 101,102,103） 向不特定对象发行可转换公司债券 募集资金使用可行性分析报告 （修订稿） 二〇二五年六月 一、本次募集资金使用计划 北京华峰测控技术股份有限公司（以下简称"华峰测控"或"公司"）拟向 不特定对象发行可转换公司债券募集资金总额不超过 74,947.51 万元（含 74,947.51 万元），扣除发行费用后的募集资金净额拟投资于以下项目： 如本次发行实际募集资金（扣除发行费用后）少于拟投入本次募集资金总额， 公司董事会将根据募集资金用途的重要性和紧迫性安排募集资金的具体使用，不 足部分将通过自筹方式解决。在不改变本次募集资金投资项目的前提下，公司董 事会（或董事会授权人士）可根据项目实际需求，对上述项目的募集资金投入顺 序和金额进行适当调整。 在本次发行可转换公司债券募集资金到位之前，公司将根据募集资金投资项 目实施进度的实际情况通过自筹资金先行投入，并在募 ...

证券代码：688200 证券简称：华峰测控 公告编号：2025-038 北京华峰测控技术股份有限公司 关于向不特定对象发行可转换公司债券摊薄即期回报与采取 填补措施及相关主体承诺（修订稿）的公告 1 况未发生重大不利变化； 2、假设本次可转换公司债券于 2025 年 6 月底完成发行，并分别假设截至 2025 年 12 月 31 日全部未转股、截至 2025 年 12 月 31 日全部完成转股两种情形。上述发 行方案实施完毕的时间和转股完成时间仅为估计，最终以经上海证券交易所发行上 市审核通过并经中国证监会同意注册后的实际发行完成时间及可转换公司债券持有 人实际完成转股的时间为准； 3、本次发行募集资金总额预计不超过人民币 74,947.51 万元（含 74,947.51 万元）， 不考虑发行费用影响，且未考虑募集资金到账后，对公司生产经营、财务状况（如 财务费用、投资收益）等的影响。本次向不特定对象发行可转换公司债券实际到账 的募集资金规模将根据监管部门审核注册情况、发行认购情况以及发行费用等情况 最终确定； 4、假设不考虑募集资金未利用前产生的银行利息以及本次可转债利息费用的影 响； 本公司及董事会全体成 ...

证券代码：688200 证券简称：华峰测控 公告编号：2025-040 北京华峰测控技术股份有限公司 第三届监事会第十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《公司法》《中华人民共和国证券法》《上市公司证券发行注册管理办 法》 等有关法律、法规和规范性文件的规定及公司股东大会的授权，根据相关 监管要 求并结合公司实际情况，公司对本次向不特定对象发行可转换公司债券 方案中的发行数量、发行规模和募集资金用途进行调整，具体内容如下： (一) 发行数量 本次修订前： 本次可转债拟发行数量为不超过 10,000,000 张（含本数）。 本次修订后： 本次可转债拟发行数量为不超过 7,494,751 张（含本数）。 (二) 发行规模 本次修订前： 北京华峰测控技术股份有限公司（以下简称"公司"）第三届监事会第十二 次会议于 2025 年 6 月 9 日在公司会议室以现场和通讯方式召开。本次会议应到 监事 3 名，实到监事 3 名。会议由监事会主席赵运坤主持。本次会议的召集和召 开符合《公司法》等法律、法规 ...

北京华峰测控技术股份有限公司 第三届董事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京华峰测控技术股份有限公司（以下简称"公司"）第三届董事会第十二次 会议于2025年6月9日上午10点30分在公司会议室以现场结合通讯表决的方式召开。 本次会议应到董事6名，实到董事6名。会议由董事长孙镪主持。本次会议的召集和召 开符合《公司法》《公司章程》的有关规定。会议以投票表决方式审议通过了以下议 案： 一、《关于修订〈公司向不特定对象发行可转换公司债券方案〉的议案》 证券代码：688200 证券简称：华峰测控 公告编号：2025-039 根据《公司法》《中华人民共和国证券法》《上市公司证券发行注册管理办法》 等有关法律、法规和规范性文件的规定及公司股东大会的授权，根据相关监管要求 并结合公司实际情况，公司董事会对本次向不特定对象发行可转换公司债券方案中 的发行数量、发行规模和募集资金用途进行调整，具体内容如下： 本次修订后： 根据相关法律法规的规定并结合公司财务状况和投资计划，本次可转债发行总 额不超过人民 ...

Group 1: Industry Overview - The electronic industry is experiencing significant improvement in H1 2025, with A-share listed companies reporting a total revenue of 859.5 billion yuan, a year-on-year increase of 18%, and a net profit of 36.6 billion yuan, up 30% year-on-year [2] - The recovery trend is clear, with Q1 2025 showing growth compared to Q4 2024, despite being a traditional off-season [2] - The semiconductor equipment domesticization rate is becoming increasingly important, especially for advanced process testing lines and domestic HBM expansion [1][7] Group 2: Segment Performance - Power and analog semiconductors are showing continuous recovery, driven by low inventory levels after two years of stock adjustments [2] - Digital ICs are experiencing strong revenue and profit growth due to AI demand, with approximately 20% growth both year-on-year and quarter-on-quarter [2] - The smartphone, PC, and tablet markets exceeded expectations in Q1 2025, with year-on-year shipment increases of 1.5%, 4.9%, and 8.5% respectively [3] Group 3: Capital Expenditure and Investment Opportunities - Capital expenditure growth for fab plants is slowing down, with SMIC's capital expenditure expected to remain flat in 2025 [1][7] - Domestic testing lines and HBM expansion are recommended areas for investment, as they are expected to perform well [1][7] - Major companies like ByteDance and Alibaba are increasing their capital expenditure, indicating a positive outlook for cloud computing and AI chip demand [6] Group 4: Emerging Technologies and Trends - AI is becoming a core focus for hardware upgrades, with numerous companies launching AI and AR products in 2025 [3] - The storage market is showing signs of recovery, with optimistic guidance from Taiwanese manufacturers regarding Q2 performance [5] - The demand for differentiated IP in SoC design is increasing, with several domestic companies making significant technological advancements [4][6]

Core Insights - The introduction of the "light asset, high R&D investment" recognition standard has led to a significant increase in the number of companies applying for refinancing on the Sci-Tech Innovation Board, with 9 companies submitting applications totaling 24.796 billion yuan [1][2] - This policy effectively addresses the financing bottleneck for "light asset, high R&D investment" enterprises, promoting resource allocation towards technological innovation [1][2] - The policy is expected to further establish the Sci-Tech Innovation Board as a core platform for nurturing new productive forces and supporting technological self-reliance [1] Group 1: Company Actions - Cambrian Technology announced a plan to raise 4.98 billion yuan through a specific issuance of A-shares, with over 30% of the funds allocated for non-capital expenditures related to R&D [1][2] - The company indicated that 87.25% of the raised funds would be used for personnel salaries and product trial costs, emphasizing its commitment to R&D [2] - Dize Pharmaceutical became the first company to complete refinancing under the new standard, adjusting its financing scale to focus on core projects, thereby accelerating its clinical and industrialization processes [3] Group 2: Industry Impact - The "light asset, high R&D investment" standard enhances the financing convenience for tech-driven companies, allowing them to increase R&D investments and improve their R&D capabilities [2][4] - The policy has improved the transparency and efficiency of refinancing reviews, providing greater flexibility for companies in need of funding [4] - It is estimated that over a hundred companies on the Sci-Tech Innovation Board may meet the "light asset, high R&D investment" criteria, although only a few have submitted refinancing applications so far [4] Group 3: Recommendations - Industry experts suggest that regulatory bodies should continue to strengthen policy promotion and provide operational guidance to help companies and intermediaries better understand and apply the new standards [5]

Core Viewpoint - The "Eight Measures for Deepening the Reform of the Sci-Tech Innovation Board" (referred to as "Eight Measures") released by the China Securities Regulatory Commission marks the beginning of a new round of reforms aimed at supporting technological innovation and new productivity development in the past year [1] Group 1: Reform Implementation and Impact - The implementation of the "light asset, high R&D investment" recognition standard has led to a surge in refinancing activities among companies on the Sci-Tech Innovation Board, with nine companies applying for refinancing totaling nearly 25 billion yuan since the standard was introduced [1][2] - The standard allows companies to use funds more flexibly, as they are no longer restricted by the previous 30% limit on supplementary working capital and debt repayment ratios [2][4] - Companies such as Cambrian and Dize Pharmaceutical have initiated significant projects in semiconductor and biopharmaceutical sectors, showcasing the vibrant innovation activity spurred by the new standard [1][2] Group 2: Company-Specific Financing Activities - Cambrian's recent fundraising of 4.98 billion yuan is the largest in its five-year history, aimed at developing chip platforms and software projects [2] - Dize Pharmaceutical's fundraising of 1.796 billion yuan is directed towards core product development and international standard innovative drug industrialization projects, with a significant portion allocated to high-uncertainty R&D expenditures [3][4] - Chip Origin's refinancing is focused on IP development, with a high percentage of funds allocated to uncertain R&D expenses, aligning with the company's strategy of maintaining high R&D investment in semiconductor technology [3][4] Group 3: Market Trends and Future Outlook - The overall market for refinancing applications has seen a notable increase since 2025, indicating a positive cycle of policy benefits leading to more active market participation [6] - The recognition standard is expected to effectively alleviate financing bottlenecks for light asset companies, enabling them to focus more on technological innovation and core competencies [6] - Over a hundred companies on the Sci-Tech Innovation Board meet the "light asset, high R&D investment" criteria, but only nine have actively pursued refinancing under the new regulations, suggesting a gradual adaptation to the new policy [6]

6月4日，寒武纪再融资申请获得上交所受理，这是又一家适用"轻资产、高研发投入"企业认定标准的再 融资案例。证券时报记者获悉，自去年10月11日上交所发布《发行上市审核规则适用指引第6号——轻 资产、高研发投入认定标准（试行）》（以下简称《指引》）以来，已有9家科创板公司按照"轻资产、 高研发投入"认定标准申请再融资，合计拟融资247.96亿元， 科创板公司再融资便利度大幅提升 "轻资产、高研发投入"认定标准的适用，有效提升了科创板公司再融资的便利度，进一步支持科技型企 业加大研发投入和提升研发水平。 此前，《证券期货法律适用意见第18号》等相关规定中虽对"轻资产、高研发投入"特点的企业做出"可 以突破补充流动资金和偿还债务比例限制"的规定，但具体认定标准未明确，实际中以个案方式推进。 《指引》对"轻资产、高研发投入"特点企业的认定标准进行了细化，符合"轻资产、高研发投入"认定标 准的企业可直接适用相关标准规划募投项目并申报再融资，进一步提高了透明度和可预期性。 此举得益于《指引》对"轻资产、高研发投入"特点企业的认定标准进行了量化。《指引》指出，具有轻 资产特点的企业，要求公司最近一年末固定资产、在建工程、土 ...

Market Performance - As of June 4, 2025, the Shanghai Composite Index rose by 0.42% to 3376.20 points, while the Shenzhen Component Index increased by 0.87% to 10144.58 points, and the ChiNext Index climbed by 1.11% to 2024.93 points [1] - The total trading volume of both markets reached 1.15 trillion yuan, marking the fifth consecutive day of exceeding one trillion yuan [1] - The jewelry sector showed strong performance with a daily increase of 5.95%, followed by leisure food and personal care products, which rose by 4.45% and 3.37% respectively [1] ETF Performance - A total of 1049 non-currency ETFs in the market increased, with an increase ratio of 91% [1] - The Hang Seng Innovative Drug Index rose by 3.83%, with related ETFs also showing significant gains of 3.61% and 3.55% [1] - The latest share size of the Hang Seng Innovative Drug ETF (520500.SH) reached 366 million shares, closely tracking the performance of the Hang Seng Innovative Drug Index [3] Valuation Metrics - The latest P/E ratio (PE-TTM) for the Hang Seng Innovative Drug Index is 26.92, which is lower than the average of over 11.03% in the past three years [4] - The P/E ratio for the Hang Seng Hong Kong Stock Connect Innovative Drug Index stands at 26.64, also below the average of over 12.16% in the last three years [5] - The National Certificate Hong Kong Stock Connect Innovative Drug Index has a P/E ratio of 29.36, lower than the average of over 10.84% in the past three years [5] Declining ETFs - A total of 71 non-currency ETFs declined, with a decrease ratio of 6% [5] - The top declining ETFs included the Greater Bay Area ETF, which fell by 1.41%, and the Transportation ETF, which decreased by 0.82% [7] Premium Rates - The S&P 500 Consumer Select Index showed a premium of 24.67%, while the S&P 500 Index had a premium of 17.11% [8] - The top ETFs by premium rate included the S&P Consumer ETF (24.67%) and the S&P 500 ETF (17.11%) [10]